期刊文献+

辛伐他汀在骨代谢中作用的研究进展 被引量:2

Research progress on the use of simvastatin in bone metabolism
下载PDF
导出
摘要 辛伐他汀是羟甲基戊二酰辅酶A还原酶的特异性抑制剂,抑制内源性胆固醇的合成。近年的研究发现:辛伐他汀可促进成骨细胞增殖和骨形成增加,因此,学者们越来越关注该药在骨改建方面的应用。大量的研究表明:将不同载体携带的辛伐他汀局部应用于各种不同的动物模型可产生不同的促骨形成效果。辛伐他汀在体内应用促进骨形成的效果取决于局部的给药质量浓度,人们一直在努力寻找合适的给药途径。本文就辛伐他汀对骨再生所产生的影响、机制、载体和剂量等作一综述。 Simvastatin is a specific hydroxymethyl glutaryl coenzyme A reductase inhibitor,which inhibits endogenous cholesterol synthesis.Recent studies have found that simvastatin could promote osteoblasts proliferation and increase bone formation,so the scholars are increasingly concerned about the drug in the application of bone remodeling.There have been a large number of studies demonstrating the bone-promoting effect of local application with different carriers in various animal models.The effect of simvastatin for bone formation in vivo depends on the concentration of local administration,and people have been trying to find a suitable route of administration.The effects of the drug on the bone metabolism and its mechanism,dosage,carrier are summarized.
作者 王蕊 吴哲
出处 《国际口腔医学杂志》 CAS 2011年第3期335-338,共4页 International Journal of Stomatology
基金 国家自然科学基金资助项目(30872912)
关键词 辛伐他汀 骨代谢 机制 载体 剂量 simvastatin bone metabolism mechanism carrier dosage
  • 相关文献

参考文献25

  • 1Jadhav SB, Jain GK. Statins and osteoporosis: New role for old drugs[J]. J Pharm Pharmaeol, 2006, 58(1):3-18.
  • 2Gutierrez GE, Lalka D, Garrett IR, et al. Transdermal ap- plication of lovastafin to rats causes profound increases in bone formation and plasma concentrations[J]. Osteo- polos Int, 2006, 17 (7) : 1033-1042.
  • 3Yamashita M, Otsuka F, Mukai T, et al. Simvastatin an- tagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentia- tion by regulating Smad signaling and Ras/Rho-mitogen- activated protein kinase pathway[J]. J Endocrinol, 2008, 196(3) :601-613.
  • 4Takenaka M, Hirade K, Tanabe K, et al. Simvastatin sti- mulates VEGF release via p44/p42 MAP kinase in vas- cular smooth muscle ceUs[J]. Biochem Biophys Res Com- mun, 2003, 301 (1) : 198-203.
  • 5Tang QO, Tran GT, Gamie Z, et al. Statins: Under inve- stigation for increasing bone mineral density and augme- nting fracture healing[J]. Expert Opin Investig Drugs, 2008, 17 (10) : 1435-1463.
  • 6Ayukawa Y, Yasukawa E, Moriyama Y, et al. Local ap- plication of statin promotes bone repair through the sup- pression of osteoclasts and the enhancement of osteo- blasts at bone-healing sites in rats[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2009, 107(3):336-342.
  • 7Yamashita M, Otsuka F, Mukai T, et al. Simvastatin in- hibits osteoclast differentiation induced by bone morpho- genetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling[J]. Regul Pept, 2010, 162 (1/2/3): 99-108.
  • 8Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins[J]. Science, 1999, 286(5446) : 1946-1949.
  • 9Sakoda K, Yamamoto M, Negishi Y, et al. Simvastatin decreases IL-6 and IL-8 production in epithelial cells [J]. J Dent Res, 2006, 85 (6):520-523.
  • 10Wu Z, Liu C, Zang G, et al. The effect of simvastatin on remodelling of the alveolar bone following tooth extra- ction[J]. Int J Oral Maxillofac Surg, 2008, 37 (2):170- 176.

同被引文献21

  • 1李晓光,高德安,张丽,王延秀,杨宪勇,王青.口腔鳞癌COX-2表达和肿瘤血管生成的研究[J].北京口腔医学,2006,14(3):164-166. 被引量:5
  • 2Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravas- tatin Pooling project [ J ]. Eur Heart J, 2002,23 ( 3 ) :207 - 215.
  • 3Hoppe C, Kuypers F, Larkin S, et al. A pilot study of the short- term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction [ J ]. Br J Haematol, 2011, 153 ( 5 ) : 655 - 663.
  • 4Song C, Guo Z, Ma Q, et al. Simvastatin induces osteoblastic dif- ferentiation and inhibits adipocytic differentiation in mouse bone marrow stromal ceils [ J]. Biochem Biophys Res Commun,2003, 308(3) :458 -462.
  • 5Nakashima M. Bone morphogenetic proteins in dentin regeneration for potential use in endodontic therapy[ J]. Cytokine Growth Fac-tor Rev,2005,16 ( 3 ) : 369 - 376.
  • 6Chen PY, Sun JS, Tsuang YH, et al. Simvastatin promotes osteo- blast viability and differentiation via Ras/Smad/Erk/BMP-2 signa- ling pathway [ J ]. Nutr Res,2010,30 (3) : 191 - 199.
  • 7Okamoto Y, Sonoyama W, Ono M, et al. Simvastatin induces the odontogenic differentiation of human dental pulp stem cells in vitro and in vivo [ J ]. J Endod ,2009,35 ( 3 ) : 367 - 372.
  • 8Abid MR, Guo S, Minami T, et al. Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial ceils [ J ]. Arterioscler Thromb Vase Biol, 2004,24 ( 2 ) :294 - 300.
  • 9Okajima E, Thorgeirsson UP. Different regulation of vascular en- dothelial growth factor expression by the ERK and p38 kinase path- ways in v-ras, v-raf, and v-myc transformed ceils [ J]. Biochem Biophys Res Commun, 2000,270 ( 1 ) : 108 - 111.
  • 10Wu HM, Yuan Y, Zawieja DC, et al. Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperper- meability[ J]. Am J Physiol,1999,276(2 Pt 2) :H535 - H542.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部